AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
motixafortide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| peptides and glycopeptides | 5744 | 664334-36-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Motixafortide is an inhibitor of the C-X-C Motif Chemokine Receptor 4 (CXCR4) and blocks the binding of its cognate ligand, stromal-derived factor-1alfa (SDF-1alfa)/C-X-C Motif Chemokine Ligand 12 (CXCL12). SDF-1alfa and CXCR4 play a role in the trafficking and homing of human hematopoietic stem cells to the marrow compartment. Once in the marrow, stem cell CXCR4 can help anchor these cells to the marrow matrix, either directly via SDF-1alfa or through the induction of other adhesion molecules. Treatment with motixafortide resulted in leukocytosis, and elevations in circulating hematopoietic stem and progenitor cells into the peripheral circulation in mice, rats, dogs, and humans. Stem cells mobilized by motixafortide were capable of engraftment with long-term repopulating capacity in a rodent transplantation model.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 8, 2023 | FDA | BIOLINERX, LTD. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L03AX23 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Other immunostimulants |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:68495 | apoptosis inducer |
| CHEBI has role | CHEBI:145438 | C-X-C chemokine receptor type 4 antagonist |
Related Drugs by ATC class:
L03AX Other immunostimulants 15 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Mobilize hematopoietic stem cells for autologous transplantation in patients with multiple myeloma | indication | 879912005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 62MG BASE/VIAL | APHEXDA | AYRMID PHARMA | N217159 | Sept. 8, 2023 | RX | POWDER | SUBCUTANEOUS | Sept. 8, 2028 | NEW CHEMICAL ENTITY |
| EQ 62MG BASE/VIAL | APHEXDA | AYRMID PHARMA | N217159 | Sept. 8, 2023 | RX | POWDER | SUBCUTANEOUS | Sept. 8, 2030 | TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| C-X-C chemokine receptor type 4 | GPCR | ANTAGONIST | Kd | 11.10 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEBI:145536 | CHEBI |
| CHEMBL5095030 | ChEMBL_ID |
| C116977 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10679 | IUPHAR_LIGAND_ID |
| DB14939 | DRUGBANK_ID |
| 4042614 | VANDF |
| C5139777 | UMLSCUI |
| CHEMBL5095449 | ChEMBL_ID |
| 10935 | INN_ID |
| D12281 | KEGG_DRUG |
| 2639893-42-6 | SECONDARY_CAS_RN |
| 91865076 | PUBCHEM_CID |
| 371181 | MMSL |
| 41953 | MMSL |
| d10105 | MMSL |
| 019555 | NDDF |
| 019556 | NDDF |
| DA9G065962 | UNII |
| 2664896 | RXNORM |
| C477728 | MESH_SUPPLEMENTAL_RECORD_UI |
| C577220 | MESH_SUPPLEMENTAL_RECORD_UI |
| C577039 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| APHEXDA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73441-062 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 62 mg | SUBCUTANEOUS | NDA | 28 sections |
| Aphexda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82737-073 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 62 mg | SUBCUTANEOUS | NDA | 16 sections |